RB, maybe, but at the annual shareholder meeting, Stoll confirmed "a couple" of patients having actually completed enrollment. Let's take the worst case scenario and say a couple more or maybe 4-5 patients have been enrolled.
Is this enough to see biological activity. Maybe, probably not, but can they afford not to roll the dice? Is there any downside here to just releasing what they have? At 15 cents a share, 8.5 million dollar market cap, running near empty on cash, on the verge of a major share increase and dilution, I just don't see the downside in releasing what they have. We're all factoring in negative outcomes here, so there wouldn't be much of a downside or surprise. Also, if they've only enrolled 3-4 patients, then there is really no purpose or reason I can see why such a trial should continue? Waiting another year or even six months is not really an option here.
Also, since we are closing in on some sort of disposition of the company, anybody who wants to assess value to Cortex must have this data endpoint. Without revealing the apnea data set results, one cannot assess an accurate value. Put it another way, if you were oging to shell out 5 or 8 or 10 million to buy Cortex out on the cheap(or more)wouldn't you want to see the apnea results? Cortex, I don't think, can selectively release this information either.
Market Data 
Markets 
AI
